Results 221 to 230 of about 504,547 (295)

Hypoxia and hypercapnia elicit overlapping but distinct skeletal muscle toxicities

The Journal of Physiology, EarlyView.
Abstract figure legend Hypoxia and hypercapnia cause overlapping skeletal muscle phenotypes, including atrophy, change in myofibre metabolic profile and myogenic response to injury. Both signals operate via distinct cellular pathways. Abstract Skeletal muscle dysfunction is strongly associated with elevated mortality in acute and chronic pulmonary ...
Joseph Balnis, Ariel Jaitovich
wiley   +1 more source

Aptamer-Based Heterobifunctional Targeted Degraders in Disease Treatment. [PDF]

Molecules
Liang X, Du M, Wang J, Lei X, Tian Y, Zhang X.   +5 more
europepmc   +1 more source

Plcg2 Deficiency Leads to Sex‐Associated Divergent Effects on Glial Transcriptomes

Glia, Volume 75, Issue 1, January 2027.
Plcg2 shapes glial programs linked to neurodegenerative disease–associated pathways in young, pathology‐free brains. Microglia and astrocytes exhibit sex‐opposing transcriptomic changes to Plcg2 deficiency. ABSTRACT Plcg2 encodes an intracellular phospholipase C signaling enzyme expressed predominately in microglia in the brain. Genome‐wide association
Kelly A. Hartigan, Luke C. Dabin, Holly N. Kersey, Nur Jury‐Garfe, Ahmad Daniel Sharify, Byungwook Kim, Bruce T. Lamb, Stephanie J. Bissel, Cristian Lasagna‐Reeves, Jungsu Kim   +9 more
wiley   +1 more source

AI-assisted design and virtual profiling of targeted degraders for pancreatic cancer therapy via PROTAC technology. [PDF]

Am J Cancer Res
Du B, Wang K, Wu Z, Qiu S, Konstantinos FD, Yu S.   +5 more
europepmc   +1 more source

Integrated single‐cell transcriptomics reveals miR‐941 targets CLDN4 to inhibit malignant progression of thyroid cancer through the PI3K/AKT signaling pathway

Journal of Cell Communication and Signaling, Volume 20, Issue 4, December 2026.
The combined single‐cell and functional analysis depicts that miR‐941 targets CLDN4 and activates the regulatory axis that drives the malignancy of thyroid cancer through the PI3K/AKT pathway. Abstract Claudin‐4 (CLDN4), a key tight junction protein, has been implicated in tumor progression; however, its functional role and regulatory mechanisms in ...
Jinghua Zhou, Tiancheng Fu, Guoxiang Huang, Guangfeng Luo, Chengcheng Wang, Yanze Wang, Ziyang Ding, Xiarong Hu, Yudong Li, Zhen Li   +9 more
wiley   +1 more source

Exploring Non-Covalent Pin1-PROTACs Insights Into Degradation Efficiency in Multiple Myeloma Cell Line. [PDF]

Chem Biodivers
Meneghelli L, Davidson S, Choi JH, Moussa SMD, Nadal S, Ravault D, Carlier L, Larregola M, Pytkowicz J, Zanato C.   +9 more
europepmc   +1 more source

A designer protein binder of KRAS enables exogenous protein degradation

Protein Science, Volume 35, Issue 12, December 2026.
Abstract Targeted protein degradation has emerged as a powerful strategy for modulating intracellular proteins, particularly those lacking traditional small‐molecule binding pockets. While protein‐based degraders expand this approach to undruggable targets, they typically require intracellular expression in target cells, limiting their utility as ...
Aniekan Okon, Keith M. Cheah, Oscar J. Molina, Gabriel Saenz, K. Dane Wittrup, Ronald T. Raines   +5 more
wiley   +1 more source

Differential ubiquitin modifications of ESCRT‐I subunits VPS37‐1 and VPS28‐2 positively regulate plant immunity

New Phytologist, Volume 252, Issue 5, Page 1988-2005, December 2026.
The RING type ubiquitin ligase (E3), XBAT35.2, positively regulates FLS2‐mediated plant immunity against bacterial pathogens by modifying the ESCRT‐I subunits VPS28‐2 and VPS37‐1 with distinct ubiquitin chain types. Summary Sensing of pathogen‐associated molecular patterns (PAMPs) by pattern recognition receptors at the cell surface initiates the first
Chaofeng Wang, Yi Zhang, Bangjun Zhou, Pooja Verma, Lirong Zeng   +4 more
wiley   +1 more source

Bispecific antibodies targeting B‐cell maturation antigen in multiple myeloma: Current clinical applications, challenges and future directions

Cancer, Volume 132, Issue 22, 15 November 2026.
Abstract Anti‐B cell maturation antigen (BCMA) therapies, including antibody‐drug conjugates, chimeric antigen receptor T cells, and bispecific antibodies (bsAbs), have recently revolutionized the treatment landscape of multiple myeloma. This review outlines the biologic rationale for targeting BCMA and sheds light on the mechanism of action of bsAbs ...
Enrica Manzato, Gloria Cocchetto, Simona Barbato, Michele Puppi, Simone Masci, Elena Zamagni   +5 more
wiley   +1 more source

Disease-guided targeted protein degradation and clearance: matching strategies to pathological protein states. [PDF]

Front Med (Lausanne)
Wang T, Ji C, Zhao T.
europepmc   +1 more source